Effects of autologous stem cell therapy for fertility enhancement among women with premature ovarian insufficiency


  • Jesmine Banu Department of Reproductive Endocrinology and Infertility, BSMMU, Dhaka, Bangladesh
  • Nishat Jahan Department of Gynecology, Nabinagar Upazilla Health Complex, Brahmanbaria, Bangladesh
  • Shaheen A. Anwary Department of Reproductive Endocrinology and Infertility, BSMMU, Dhaka, Bangladesh
  • Mostafa Tarique Department of Reproductive Endocrinology and Infertility, BSMMU, Dhaka, Bangladesh
  • Itrat Aziz Department of Reproductive Endocrinology and Infertility, BSMMU, Dhaka, Bangladesh
  • Nastaran Laskar Department of Reproductive Endocrinology and Infertility, BSMMU, Dhaka, Bangladesh
  • M. Rifat Hasan Department of Transfusion Medicine, BSMMU, Dhaka, Bangladesh
  • Chowdhury F. Alamgir Department of Urology, New Cross Hospital, The Royal Wolverhampton NHS Trust, United Kingdom
  • Maliha Darmini Department of Gynecology, New Cross Hospital, The Royal Wolverhampton NHS Trust, United Kingdom




Autologous, Ovarian, Pregnancy, Fertility, Infertility, Stem-cell


Background: Premature ovarian insufficiency (POI) is a condition where the ovary loses its normal reproductive potential earlier than 40 years, compromising fertility. There is no treatment for POI, only ovum or embryo donation. Autologous stem cell ovarian transplant (ASCOT) may be a procedure that creates new eggs in the ovaries of women with POI. The aim of the study was to find out the efficacy of ASCOT in patients suffering from POI.

Methods: A total of 50 patients were included according to inclusion and exclusion criteria in this prospective observational study. POI was confirmed with low levels of anti-mullerian hormone (AMH) (<0.5 ng/dl), high level of follicle stimulating hormone (FSH) >25 ng/ml, and or a low number of antral follicle count (AFC) (<3 in each ovary).

Results: Results showed that after stem cell therapy, mean AMH values increased by 0.48±0.306 and mean FSH values increased by 2.73±3.98 but the difference was not statistically significant. AFC values significantly decreased by 1.33±0.625 at 1st post-stem-cell cycle. During the second cycle, AMH and AFC increased by 0.110±0.051 and 4.63±1.49, respectively, and FSH decreased by 7.4±2.78. In third cycle, AMH & FSH was significantly increased by 0.820±0.44 & 4.120±0.470 and FSH has been decreased by 2.150±3.625. The increase in AMH & AFC was statistically significant, and the decrease in FSH was not statistically significant compared to baseline values.

Conclusions: The study showed that autologous stem cell therapy can have a significant effect on women’s ovarian function and fertility. It showed that ASCOT can increase AMH and AFC, and decrease FSH in patients with POI, with a total pregnancy rate of 4% after the third cycle follow-up.


Broekmans FJ, Knauff EA, te Velde ER, Macklon NS, Fauser BC. Female reproductive ageing: current knowledge and future trends. Trends Endocrinol Metabol. 2007;18(2):58-65.

Ulrich ND, Marsh EE. Ovarian reserve testing: A review of the options, their applications, and their limitations. Clin Obstet Gynecol. 2019;62(2):228.

Park SU, Walsh L, Berkowitz KM. Mechanisms of ovarian aging. Reproduction. 2021;162(2):R19-33.

Shelling AN. Premature ovarian failure. Reproduction, 2010;140(5):633.

Arora P, Polson DW. Diagnosis and management of premature ovarian failure. Obstet Gynaecol. 2011;13(2):67-72.

Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67(4):604-6.

Michalakis K, Coppack SW. Primary ovarian insufficiency: relation to changes in body composition and adiposity. Maturitas. 2012;71(4):320-5.

Maclaran K, Panay N. Premature ovarian failure. BMJ Sexual Reprod Health. 2011;37(1):35-42.

Bachelot A, Nicolas C, Bidet M, Dulon J, Leban M, Golmard JL, et al. Long‐term outcome of ovarian function in women with intermittent premature ovarian insufficiency. Clin Endocrinol. 2017;86(2):223-8.

Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Human Reprod Update. 2012;18(1):73-91.

Zuckerman S. The number of oocytes in the mature ovary. Recent Progress Hormone Res. 1951;6:63-109.

Johnson NP, Bagrie EM, Coomarasamy A, Bhattacharya S, Shelling AN, Jessop S, et al. Ovarian reserve tests for predicting fertility outcomes for assisted reproductive technology: the International Systematic Collaboration of Ovarian Reserve Evaluation protocol for a systematic review of ovarian reserve test accuracy. BJOG. 2006;113(12):1472-80.

Wang N, Tilly JL. Epigenetic status determines germ cell meiotic commitment in embryonic and postnatal mammalian gonads. Cell Cycle. 2010;9(2):339-49.

Niikura Y, Niikura T, Tilly JL. Aged mouse ovaries possess rare premeiotic germ cells that can generate oocytes following transplantation into a young host environment. Aging (Albany NY). 2009;1(12):971.

Frese L, Dijkman PE, Hoerstrup SP. Adipose tissue-derived stem cells in regenerative medicine. Transfusion Med Hemotherap. 2016;43(4):268-74.

Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circulation Res. 2008;103(11):1204-19.

Herraiz S, Romeu M, Buigues A, Martínez S, Díaz-García C, Gómez-Seguí I, et al. Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. Fertil Steril. 2018;110(3):496-505.

Ludwin A, Ludwin I, Kudla M, Kottner J. Reliability of the European Society of Human Reproduction and Embryology/European Society for Gynaecological Endoscopy and American Society for Reproductive Medicine classification systems for congenital uterine anomalies detected using three-dimensional ultrasonography. Fertil Steril. 2015;104(3):688-97.

Taylor AE. Systemic adversities of ovarian failure. J Soc Gynecol Investig. 2001;8(1):S7-9.

Pouresmaeili F, Fazeli Z. Premature ovarian failure: a critical condition in the reproductive potential with various genetic causes. Int J Fertil Steril. 2014;8(1):1.

Fenton AJ. Premature ovarian insufficiency: Pathogenesis and management. J Mid-life Health. 2015;6(4):147.

Eshre Guideline Group on POI, Webber L, Davies M, Anderson R, Bartlett J, Braat D, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Human Reprod. 2016;31(5):926-37.

Blumenfeld Z. Fertility treatment in women with premature ovarian failure. Expert Rev Obstet Gynecol. 2011;6(3):321-30.

Definition of autologous stem cell transplant - NCI Dictionary of Cancer Terms .2011. National Cancer Institute. Available at: https://www.cancer.gov/ publications/dictionaries/cancer-terms/def/auto logous-stem-cell-transplant. Accessed on 30 October 2022.

Saha S, Roy P, Corbitt C, Kakar SS. Application of Stem Cell Therapy for Infertility. Cells. 2021;10(7):1613.

Fang F, Li Z, Zhao Q, Li H, Xiong C. Human induced pluripotent stem cells and male infertility: an overview of current progress and perspectives. Human Reprod. 2018;33(2):188-95.

Abd-Allah SH, Shalaby SM, Pasha HF, Amal S, Raafat N, Shabrawy SM, et al. Mechanistic action of mesenchymal stem cell injection in the treatment of chemically induced ovarian failure in rabbits. Cytotherapy. 2013;15(1):64-75.

Mohamed SA, Shalaby SM, Abdelaziz M, Brakta S, Hill WD, Ismail N, Al-Hendy A. Human mesenchymal stem cells partially reverse infertility in chemotherapy-induced ovarian failure. Reprod Sci. 2018;25(1):51-63.

Santamaria X, Cabanillas S, Cervelló I, Arbona C, Raga F, Ferro J, Palmero J, Remohí J, Pellicer A, Simón C. Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman's syndrome and endometrial atrophy: a pilot cohort study. Human Reprod. 2016;31(5):1087-96.

Wang J, Liu C, Fujino M, Tong G, Zhang Q, Li XK, Yan H. Stem cells as a resource for treatment of infertility-related diseases. Curr Mol Med. 2019;19(8):539-46.

Dunlop CE, Telfer EE, Anderson RA. Ovarian stem cells—potential roles in infertility treatment and fertility preservation. Maturitas. 2013;76(3):279-83.

“Primary Ovarian Insufficiency”. Endocrine System. 2003. Available at: https://medlineplus.gov/primary ovarianinsufficiency.html. Accessed on 30 October 2022.

Follicle-stimulating hormone (FSH) blood test. Mount Sinai Health System. Available at: https://www.mountsinai.org/health-library/tests/ follicle-stimulating-hormone-fsh-blood-test. Accessed on 30 October 2022.

Na J, Kim GJ. Recent trends in stem cell therapy for premature ovarian insufficiency and its therapeutic potential: a review. J Ovarian Res. 2020;13(1):74.

Igboeli P, El Andaloussi A, Sheikh U, Takala H, ElSharoud A, McHugh A, et al. Intraovarian injection of autologous human mesenchymal stem cells increases estrogen production and reduces menopausal symptoms in women with premature ovarian failure: two case reports and a review of the literature. J Med Case Rep. 2020;14(1):1.

Uddin MJ, Banu J, Ishrat S, Sultana S, Munira S, Shume MM, et al. Effect of autologous platelet rich plasma on anti-mullerian hormone and antral follicle count in sub fertile women with poor ovarian reserve. Int J Reprod Contracept Obstet Gynecol. 2022;11(2):292-9.

Xiao GY, Liu IH, Cheng CC, Chang CC, Lee YH, Cheng WT, et al. Amniotic fluid stem cells prevent follicle atresia and rescue fertility of mice with premature ovarian failure induced by chemotherapy. PLoS One. 2014;9(9):e106538.

Zhang Q, Xu M, Yao X, Li T, Wang Q, Lai D. Human amniotic epithelial cells inhibit granulosa cell apoptosis induced by chemotherapy and restore the fertility. Stem Cell Res Therap. 2015;6(1):1-0.

Ling L, Feng X, Wei T, Wang Y, Wang Y, Wang Z, et al. Human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation improves ovarian function in rats with premature ovarian insufficiency (POI) at least partly through a paracrine mechanism. Stem Cell Res Therap. 2019;10(1):1-8.

Huang B, Ding C, Zou Q, Lu J, Wang W, Li H. Human amniotic fluid mesenchymal stem cells improve ovarian function during physiological aging by resisting DNA damage. Front Pharmacol. 2020;11:272.

Feng P, Li P, Tan J. Human menstrual blood-derived stromal cells promote recovery of premature ovarian insufficiency via regulating the ECM-dependent FAK/AKT signaling. Stem Cell Rev Rep. 2019;15(2):241-55.






Original Research Articles